Mania in a patient using cannabidiol for neuropathic pain
Industrial Psychiatry Journal · 21.04.2026
DOI: 10.4103/ipj.ipj_409_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Industrial Psychiatry Journal, online erschienen am 21.04.2026. Verfasst von Varchasvi Mudgal und 3 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Dear Editor, Cannabidiol (CBD), a nonintoxicating phytocannabinoid derived from Cannabis sativa, has gained rapid popularity as a treatment for conditions such as neuropathic pain, anxiety, and epilepsy. It is often promoted as safer than Δ 9-tetrahydrocannabinol (THC) because it lacks psychotomimetic effects.[1] Despite this perception, the neuropsychiatric safety of CBD remains incompletely understood. While studies suggest anxiolytic and antipsychotic properties,[2] emerging evidence raises concerns regarding paradoxical effects, including agitation, affective instability, and psychosis.[3] We report the case of a 26-year-old male with no psychiatric or substance use history who presented with acute mania after 3 months of escalating CBD use. Initially prescribed 100 mg/day CBD solution for neuropathic pain, he self-titrated up to 300–400 mg/day. Over the preceding week, he developed irritability, reduced need for sleep, pressured speech, grandiose ideas, heightened activity, and aggression. His Young Mania Rating Scale (YMRS) score was 34, indicating severe mania. Toxicology was negative for alcohol, opioids, and stimulants. No neurological or medical cause was identified. He was admitted to a psychiatric unit. CBD was discontinued, and treatment with sodium valproate (1000 mg/day) and olanzapine (10 mg/day) was initiated. Within 2 weeks, his manic symptoms markedly subsided, and YMRS score reduced to 8 at discharge. He regained insight and was educated about risks of unsupervised cannabinoid use. No recurrence was reported on follow-up. This case suggests that high-dose CBD may precipitate mania even in individuals without psychiatric vulnerability. The temporal association between dose escalation and symptom onset, together with resolution after discontinuation, supports a pharmacologically induced mood episode rather than the emergence of bipolar disorder. CBD interacts with serotonergic and vanilloid receptor systems (5-HT1A, TRPV1), which influence arousal and mood regulation.[4] These mechanisms may explain why low-to-moderate doses appear anxiolytic, while higher doses destabilize mood. The clinical implications are significant. CBD is increasingly available in unregulated formulations, with studies showing inaccuracies in product labeling and variability in concentration and purity.[5] Patients often self-adjust dosing, believing CBD to be inherently safe. Such practices may increase the risk of psychiatric side effects, particularly mania, which can present abruptly and severely. Further systematic research and pharmacovigilance are required to clarify dose-related neuropsychiatric risks, establish safe prescribing guidelines, and ensure quality control of cannabinoid products. Until then, cautious prescribing and close monitoring remain essential. Authors’ contributions All authors contributed to all stages of manuscript preparation and final approval of the manuscript. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Zitieren
APA
Mudgal, V., Mathur, R., Jain, P., & Gaurav, P. (2026). Mania in a patient using cannabidiol for neuropathic pain. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_409_25
Vancouver
Mudgal V, Mathur R, Jain P, Gaurav P. Mania in a patient using cannabidiol for neuropathic pain. Industrial Psychiatry Journal. 2026. doi:10.4103/ipj.ipj_409_25
BibTeX
@article{Mudgal2026,
author = {Mudgal, Varchasvi and Mathur, Rahul and Jain, Priyash and Gaurav, Prashant},
title = {Mania in a patient using cannabidiol for neuropathic pain},
journal = {Industrial Psychiatry Journal},
year = {2026},
doi = {10.4103/ipj.ipj_409_25}
}
EUVIMED